Lennox-Gastaut%2520syndrome

# Lennox-Gastaut Syndrome (LGS) ## Overview Lennox-Gastaut syndrome is a severe, childhood-onset epilepsy syndrome characterized by multiple seizure types (tonic, atonic, absence), slow spike-wave EEG patterns, and intellectual impairment. Treatment is often refractory, requiring polypharmacy. ## Primary Indications Adjunctive treatment of seizures associated with LGS in patients typically ≥1 to ≥2 years of age. ## Adult Dosing Relevant medications for LGS generally follow titration schedules to minimize CNS side effects: * **Rufinamide:** Start 400–800 mg/day in two divided doses; increase by 400–800 mg/day every 2 days to max 3200 mg/day (or 45 mg/kg/day). * **Clobazam:** Start 5 mg/day; increase to 20 mg/day over 2 weeks. Max: 40 mg/day. * **Cannabidiol (Epidiolex):** Start 2.5 mg/kg twice daily (5 mg/kg/day); increase to 5 mg/kg twice daily (10 mg/kg/day) after 1 week. May increase to 20 mg/kg/day based on tolerance. * **Topiramate:** Start 25 mg/day; titrate weekly by 25–50 mg. Target 200–400 mg/day. * **Felbamate:** Start 1200 mg/day in three divided doses; increase in 1200 mg increments every week. Max: 3600 mg/day (requires strict informed consent). ## Pediatric Dosing Dosing is weight-based (usually ≥1 year): * **Rufinamide:** 10 mg/kg/day initially, divided BID; increase by 10 mg/kg/day every 2 days. Max: 45 mg/kg/day (not to exceed 3200 mg/day). * **Cannabidiol:** Same as adult (mg/kg basis). * **Clobazam:** Weight <30 kg: Start 5 mg/day; target 0.2–0.3 mg/kg/day. Weight ≥30 kg: Start 10 mg/day; target 20 mg/day. * **Rufinamide (1-4 years):** Often requires specialized titration due to higher clearance rates in younger children. ## Dose Adjustments * **Renal:** Clobazam and Topiramate require dose reduction in severe impairment. Rufinamide is not recommended in severe renal impairment. * **Hepatic:** Adjustments mandatory for Cannabidiol (lower starting/maintenance doses) and Clobazam. Avoid Felbamate or use with extreme caution due to hepatotoxicity. ## Contraindications * **Rufinamide:** Familial Short QT syndrome. * **Felbamate:** History of hepatic impairment or bone marrow suppression. * **General:** Known hypersensitivity to the specific agent or its excipients. ## Adverse Effects * **Common:** Somnolence, fatigue, dizziness, ataxia, irritability, and decreased appetite. * **Specific:** * **Rufinamide:** Shortened QT interval. * **Cannabidiol:** Elevated transaminases (ALT/AST), diarrhea. * **Felbamate:** Aplastic anemia, acute liver failure (Black Box Warnings). * **Topiramate:** Metabolic acidosis, nephrolithiasis, cognitive slowing ("dopamax"). ## Key Drug Interactions * **Clobazam:** Potent CYP2C19 interaction (may increase concentrations of other AEDs). * **Cannabidiol:** Significant interaction with Clobazam (increases N-desmethylclobazam levels, increasing toxicity risk) and Valproate (increases risk of ALT elevation). * **Enzyme Inducers:** Carbamazepine, phenytoin, and phenobarbital decrease levels of many LGS-adjunct medications. ## Monitoring * **CBC and LFTs:** Required for Felbamate and Cannabidiol. * **ECG:** Mandatory for Rufinamide (baseline and during titration). * **Serum Bicarbonate:** Monitor for topiramate-induced metabolic acidosis. * **Neurologic:** Monitor for increased seizure frequency (paradoxical) and suicidal ideation (class-wide risk). ## Clinical Pearls * **Titration:** LGS medications must be titrated slowly to avoid intolerable CNS sedation. * **Polypharmacy:** Patients are almost always on multiple agents; focus focus on identifying the "main" driver of side effects (e.g., elevated N-desmethylclobazam). * **Rescue:** Clobazam is frequently used as a rescue medication because of its long half-life, but tolerance can develop. * **Local Protocol:** Dosing protocols, particularly for rapid titration or transition between agents, vary by epilepsy center; always consult local pediatric neurology guidelines. *** *Disclaimer: This information is for educational purposes and does not substitute for clinical judgment. Dosing and clinical practices should be verified against current institutional protocols, primary literature, and official FDA/EMA prescribing information.*